Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
This opportunity supports research that uses data from expanded access (EA) to investigational ALS drugs or biological products. It targets intermediate-sized patient groups of people living with ALS who cannot join ongoing ALS prevention, diagnosis, mitigation, treatment, or cure clinical trials. Clinical trial involvement is required.
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
National Institutes of Health
-
NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)
National Institutes of Health
-
NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
National Institutes of Health
-
NIH Midcareer Investigator Award in Patient-Oriented Research (K24)
National Institutes of Health
-
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
National Institutes of Health
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers